Servier taps India as global hub for single‑pill combination drugs, targets 500 mn euro exports by 2030

Servier

• Servier launches GATINN in Mumbai to develop and export SPC therapies globally
• GATINN plans €15M investment, targets €500M exports by 2030
• First international SPC launch in Q2 2027; five products by end-2026.

Did our AI summary help?

Servier is positioning India as a global springboard for its fast‑growing single pill combination (SPC) business, unveiling a new platform—GATINN—that will develop, manufacture and export combination therapies for cardiometabolic and venous diseases.

The French drugmaker will invest 15 million euro in 2026 to build the platform, which will coordinate R&D, manufacturing partnerships and quality oversight in India. The company is also aiming directionally for GATINN to reach 500 million euro in global exports by 2030, signalling the strategic weight India now holds in Servier’s long‑term growth plan.

GATINN, headquartered in Mumbai, is designed as a dedicated Indo‑French collaboration model, blending Servier’s scientific and originator‑API capabilities with India’s development and manufacturing ecosystem. It will work with selected Indian CDMOs to produce SPCs while Servier continues to supply the active pharmaceutical ingredients from its global production network.

The first international launch from the platform is expected in Q2 2027, with around five SPCs already lined up for development by end‑2026 and an additional product expected each year through 2030.

Combination therapies or two in one pill or three in one pill, offers convenience for consumers, improves adherence and are more affordable than taking each single pill. While India is not new to combination pills, but in most countries, combination pills require bioequivalence and in certain cases safety studies and regulatory approvals, to ensure there is no side-effects or drug-drug reactions. However one-limitation with combination pills  is dose titration or adjustment of dosage—upward or downward based on patient requirement. This is can be overcome by launching SPCs in different dosage strengths.

“GATINN embodies Servier’s strategy to address critical patient unmet needs by accelerating patient‑centric innovation,” said Dr. Kshitij Panse, COO of GATINN. He added that “‘Gati’ signifies speed and ‘Inn’ innovation in India,” highlighting how the company intends to use India’s cost‑efficient, high‑quality manufacturing strengths to deliver global‑standard therapies faster. Servier executives said the platform aims to simplify treatment regimens, boost adherence, and improve long‑term outcomes for chronic disease patients globally—especially in markets where adherence gaps remain a significant medical challenge.

Servier’s leadership emphasised that this is the company’s first such global coordination platform outside France.

“The decision to establish GATINN in India aligns with our strategy to advance patient‑centered innovation,” said Charlotte Marmousez, Executive Vice President, Corporate Strategy & Transformation. Philippe Gonnard, EVP, Global Product Strategy, added that the initiative “reflects our long‑term, patient‑centric approach—building capabilities where they create the greatest patient value.” Servier Operations EVP Stéphane Mascarau said the company will prioritise rapid rollout of India‑developed SPCs across Asia, Latin America, the Middle East and Africa. Servier India

Managing Director Aurelien Breton said GATINN “reinforces our long‑term commitment to India and strengthens our presence in the country.”

Servier is an independent, foundation‑governed global pharmaceutical group headquartered in France, posting €6.9 billion in revenues in FY2024/25.

The company operates in more than 130 countries, employs over 20,000 people, and reinvests nearly 20% of its brand‑name sales into R&D.

In India, Servier has operated for around four decades, with strengths in cardiometabolism, venous diseases and oncology, and forms a key part of the group’s global footprint and growth ambitions.

Please read here on company's growth strategy in India.